Heinonen EH - Search Results

1

Selegiline in the treatment of narcolepsy.

Hublin C, Partinen M, Heinonen EH, Puukka P, Salmi T. Hublin C, et al. Among authors: heinonen eh. Neurology. 1994 Nov;44(11):2095-101. doi: 10.1212/wnl.44.11.2095. Neurology. 1994. PMID: 7969965 Clinical Trial.

2

Selegiline as initial treatment in de novo parkinsonian patients.

Myllylä VV, Sotaniemi KA, Vuorinen JA, Heinonen EH. Myllylä VV, et al. Among authors: heinonen eh. Neurology. 1992 Feb;42(2):339-43. doi: 10.1212/wnl.42.2.339. Neurology. 1992. PMID: 1736162 Clinical Trial.

3

Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.

Olanow CW, Myllylä VV, Sotaniemi KA, Larsen JP, Pålhagen S, Przuntek H, Heinonen EH, Kilkku O, Lammintausta R, Mäki-Ikola O, Rinne UK. Olanow CW, et al. Among authors: heinonen eh. Neurology. 1998 Sep;51(3):825-30. doi: 10.1212/wnl.51.3.825. Neurology. 1998. PMID: 9748034

4

Selegiline slows the progression of the symptoms of Parkinson disease.

Pålhagen S, Heinonen E, Hägglund J, Kaugesaar T, Mäki-Ikola O, Palm R; Swedish Parkinson Study Group. Pålhagen S, et al. Neurology. 2006 Apr 25;66(8):1200-6. doi: 10.1212/01.wnl.0000204007.46190.54. Epub 2006 Mar 15. Neurology. 2006. PMID: 16540603 Clinical Trial.

5

Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group.

Pålhagen S, Heinonen EH, Hägglund J, Kaugesaar T, Kontants H, Mäki-Ikola O, Palm R, Turunen J. Pålhagen S, et al. Among authors: heinonen eh. Neurology. 1998 Aug;51(2):520-5. doi: 10.1212/wnl.51.2.520. Neurology. 1998. PMID: 9710028 Clinical Trial.

6

Vincristine treatment of acute lymphoblastic leukemia induces transient autonomic cardioneuropathy.

Hirvonen HE, Salmi TT, Heinonen E, Antila KJ, Välimäki IA. Hirvonen HE, et al. Cancer. 1989 Aug 15;64(4):801-5. doi: 10.1002/1097-0142(19890815)64:4<801::aid-cncr2820640406>3.0.co;2-e. Cancer. 1989. PMID: 2743273

7

Selegiline as the primary treatment of Parkinson's disease--a long-term double-blind study.

Myllylä VV, Sotaniemi KA, Hakulinen P, Mäki-Ikola O, Heinonen EH. Myllylä VV, et al. Among authors: heinonen eh. Acta Neurol Scand. 1997 Apr;95(4):211-8. doi: 10.1111/j.1600-0404.1997.tb00101.x. Acta Neurol Scand. 1997. PMID: 9150811 Clinical Trial.

8

Selegiline as a primary treatment of Parkinson's disease.

Myllylä VV, Sotaniemi KA, Vuorinen JA, Heinonen EH. Myllylä VV, et al. Among authors: heinonen eh. Acta Neurol Scand Suppl. 1991;136:70-2. doi: 10.1111/j.1600-0404.1991.tb05023.x. Acta Neurol Scand Suppl. 1991. PMID: 1801540 Clinical Trial.

9

Role of selegiline in combination therapy of Parkinson's disease.

Myllylä VV, Sotaniemi K, Mäki-Ikola O, Rinne UK, Heinonen EH. Myllylä VV, et al. Among authors: heinonen eh. Neurology. 1996 Dec;47(6 Suppl 3):S200-9. doi: 10.1212/wnl.47.6_suppl_3.200s. Neurology. 1996. PMID: 8959989 Review. No abstract available.

10

Early selegiline therapy reduces levodopa dose requirement in Parkinson's disease.

Myllylä VV, Heinonen EH, Vuorinen JA, Kilkku OI, Sotaniemi KA. Myllylä VV, et al. Among authors: heinonen eh. Acta Neurol Scand. 1995 Mar;91(3):177-82. doi: 10.1111/j.1600-0404.1995.tb00429.x. Acta Neurol Scand. 1995. PMID: 7793231 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

97 results

Search Page

Filters